上海醫藥(601607.SH):維立西呱原料藥上市申請獲得批準
格隆匯5月12日丨上海醫藥(601607.SH)公佈,公司下屬控股子公司南通常佑藥業科技有限公司(以下簡稱“南通常佑”)的維立西呱原料藥(以下簡稱“該藥物”)收到國家藥品監督管理局頒發的《化學原料藥上市申請批準通知書》(通知書編號:2025YS00363),該藥物獲得批準生產。
維立西呱主要適用於近期心力衰竭失代償經靜脈治療後病情穩定的射血分數降低(射血分數<45%)的症狀性慢性心力衰竭成人患者,以降低發生心力衰竭住院或需要急診靜脈利尿劑治療的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.